Juno buys AbVitro for $132mm in cash and stock
Juno Therapeutics Inc. acquired privately held AbVitro Inc. (next-generation single cell sequencing) for $78mm in cash and 1.3mm Juno shares (valued at about $54mm based on the pre-announcement market average).
- Research, Analytical Equipment & Supplies
- Gene Therapy, Cell Therapy
Drug Discovery Tools
- Acquisition of Private Biotech
- Full Acquisition
- Includes Contract
- Intra-Biotech Deal
- Payment Includes Cash
- Payment Includes Stock
Please contact Sales at: (212) 520-2765 or email [email protected]
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.